Drug
Sgn 40
Sgn 40: highest development phase Phase 2, developed by Seagen. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| SGN-40 NCT00529503 | Phase 2 | Lymphoma, Large B-Cell, Diffuse |
| SGN-40 (anti-huCD40 mAb) NCT00103779 | Phase 1 | Non-Hodgkin Lymphoma |
Latest
No recent events.
Follow Sgn 40 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.